One Stop Solution For In-Depth Market Research Reports

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Lung Cancer Surgery Market

Lung Cancer Surgery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Product Code : MDHC00122343
Survey : Mordor Intelligence
Publish On : 12, August, 2022
Category : Healthcare and Pharmaceuticals
Study Area : North America (U.S. and Others), Europe (Germany, France, U.K. and Others), Asia-Pacific (Japan, China, India and Others), Rest of World (Brazil, Rest of Latin America, Middle East & Others)
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
 - Accuray Incorporated
- GE Healthcare
- Johnson & Johnson
- Olympus Corporation
- Richard Wolf GmbH
- Siemens Healthineers AG
- AngioDynamics Inc.

[Report Description]

Rising air pollution and people getting affected by it are one of the prime factors responsible for the growth of the market for lung cancer surgery. As per an article by the Vital Strategies Environmental Health Division staff, 2018, while most of the 4.2 million premature deaths linked to air pollution are due to heart disease and strokes, around 1.7 million deaths are from lung cancer and other respiratory diseases globally. According to the WHO database, levels of ultra-fine particles of less than 2.5 microns are highest in India, which has 16 of the world’s 30 most polluted cities. Thus, a rise in air pollution is, primarily, driving the lung cancer rate, and hence the studied market is expected to be impacted.

Key Market Trends

Segmentectomy is Expected to Witness High Growth

With the growing prevalence of lung cancer and technological development, the therapy line has also been improved and people can start taking treatment from the early stage, these factors are expected to further boost the growth of the lung cancer surgery market.

Segmentectomy is a common surgical treatment that can be an option to treat non-small cell lung cancer (NSCLC). It is mostly recommended over lobectomy if the patient already has a highly reduced lung reserve. Although lung segmentectomy has always been popular for resection of supportive lesions and nonmalignant masses, most of the time it is recommended for very early lung cancer.

The growing popularity of this technique is because of better outcomes, less pain, and shorter recovery than traditional surgical techniques. Segmentectomy procedure has a good success rate for removing localized tumors and cancers with higher survival rates, with the retention of organ functions up to a certain degree and these advantages are anticipated to fuel the studied market growth.

However, there are some risks associated with segmentectomy arising from general anesthesia, which raises the chances of excessive bleeding, blood clot formation, pneumonia, and infection of the surgical wound.

North America is Expected to Dominate the Market

As per the American Cancer Society’s estimation, the new cases of lung cancer in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved and the incidence of localized lung cancer has increased.

According to the American Lung Association (2018), approximately 541,000 Americans living today have been diagnosed with lung cancer at some point in their lives. The majority of lung cancer patients have been diagnosed within the last five years. Each year, around tens of thousands of people, are cured of non-small cell lung cancer (NSCLC) in the United States. Lung cancer is mostly a disease of the elderly. This indicates the burden of lung cancer in this country and this is resulting in the growth of the market studied as there is a high demand for cancer treatment in the United States.

Competitive Landscape

The lung cancer surgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products at cheaper prices.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format

  • 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Lung Cancer
4.2.2 Technological Advancements in the Field of Minimally Invasive Surgeries
4.2.3 Rise in the Level of Air Pollution
4.3 Market Restraints
4.3.1 Effective Alternative Treatment
4.4 Porter s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Thoracotomy Lobectomy Sleeve Resection Segmentectomy Pneumonectomy
5.1.2 Minimally Invasive Surgeries
5.2 By Product
5.2.1 Surgical Devices
5.2.2 Monitoring Devices
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Accuray Incorporated
6.1.2 GE Healthcare
6.1.3 Johnson & Johnson
6.1.4 Olympus Corporation
6.1.5 Richard Wolf GmbH
6.1.6 Siemens Healthineers AG
6.1.7 AngioDynamics Inc.


Shibuya data count

Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.

Recommended reports